DISC MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.53 USD | +2.48% |
|
+4.51% | -50.61% |
| Apr. 08 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
| Apr. 02 | Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 336.6 | 1,394 | 704.1 | - | - |
| Enterprise Value (EV) 1 | 142 | 1,394 | 338.3 | 342.6 | 375.4 |
| P/E ratio | -0.44 x | -16.9 x | -6.44 x | -5.57 x | -4.52 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 220 x |
| EV / Revenue | - | - | - | - | 117 x |
| EV / EBITDA | - | -15.3 x | -3.07 x | -2.19 x | -2.21 x |
| EV / FCF | - | - | -3.39 x | -3.23 x | -3.02 x |
| FCF Yield | - | - | -29.5% | -30.9% | -33.1% |
| Price to Book | - | - | 1.83 x | 1.75 x | 2.57 x |
| Nbr of stocks (in thousands) | 16,923 | 24,140 | 24,681 | - | - |
| Reference price 2 | 19.89 | 57.76 | 28.53 | 28.53 | 28.53 |
| Announcement Date | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3.2 |
| EBITDA 1 | - | - | -91.02 | -110.3 | -156.6 | -169.8 |
| EBIT 1 | - | -47.48 | -91.12 | -132.9 | -146.3 | -171.3 |
| Operating Margin | - | - | - | - | - | -5,352.88% |
| Earnings before Tax (EBT) 1 | - | -46.83 | -76.33 | -111.2 | -134.9 | -159.9 |
| Net income 1 | -35.97 | -46.83 | -76.43 | -111.7 | -137.4 | -174.2 |
| Net margin | - | - | - | - | - | -5,444.13% |
| EPS 2 | -4.490 | -45.05 | -3.420 | -4.427 | -5.123 | -6.310 |
| Free Cash Flow 1 | - | - | - | -99.9 | -106 | -124.3 |
| FCF margin | - | - | - | - | - | -3,885.42% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/2/22 | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -15.02 | -25.12 | -17.33 | -18.96 | -29.71 | -26.96 | -26.69 | -27.27 | -33.39 | -25 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -11.24 | -22.76 | -15.92 | -14.1 | -23.55 | -24.44 | -24.92 | -25.51 | -31.62 | -25 |
| Net income 1 | -16.15 | -11.24 | -22.78 | -15.95 | -14.12 | -23.58 | -24.96 | -25.5 | -26.27 | -31.4 | -25 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.860 | -40.91 | -1.200 | -0.7400 | -0.5800 | -0.9700 | -1.037 | -1.072 | -1.110 | -1.247 | -1.120 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/23/22 | 3/31/23 | 5/15/23 | 8/11/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 195 | - | 366 | 362 | 329 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -99.9 | -106 | -124 |
| ROE (net income / shareholders' equity) | - | - | - | -24.5% | -29.3% | -33.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 15.60 | 16.30 | 11.10 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 0.15 | - | 0.15 | 2.55 | 5.05 |
| Capex / Sales | - | - | - | - | - | 157.81% |
| Announcement Date | 9/2/22 | 3/31/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.53
USD
Average target price
57.11
USD
Spread / Average Target
+100.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.61% | 687M | |
| +0.67% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +6.55% | 24.63B | |
| -21.66% | 18.2B | |
| +29.96% | 12.01B | |
| -1.57% | 11.76B | |
| +16.03% | 10.4B | |
| -4.80% | 9.94B |
- Stock Market
- Equities
- IRON Stock
- Financials Disc Medicine, Inc.
